Is intramuscular ketorolac appropriate for a 10-year-old patient?

Intramuscular Ketorolac in a 10-Year-Old Patient

Ketorolac IM is not FDA-approved for pediatric use and should not be administered to a 10-year-old patient. The FDA drug label explicitly states that "ketorolac tromethamine is not indicated for use in pediatric patients" and that "the safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 17 have not been established" 1.

Key FDA Labeling Restrictions

The FDA has not approved ketorolac for any route of administration in children under 17 years of age 1. Critically, there are no pharmacokinetic data available for intramuscular ketorolac administration in pediatric patients 1. The only pediatric pharmacokinetic data available are for intravenous administration in children aged 4-8 years, which showed higher volume of distribution and clearance compared to adults 1.

Clinical Practice Context

While the FDA labeling is clear, clinical practice has diverged from this restriction:

Evidence from Guidelines

The 2021 American Association for Thoracic Surgery consensus document discusses intravenous ketorolac (not IM) as part of multimodal pain regimens in pediatric cardiac surgery, noting it may be opioid-sparing but carries risks of acute kidney injury and bleeding 2. However, these guidelines emphasize specific cautions:

• Avoid in infants under 6 months due to significant creatinine increases 2
• Use with extreme caution in patients with preexisting renal dysfunction, concomitant aspirin use, or single-ventricle palliation 2
• Associated with acute kidney injury and increased bleeding risk 2

Route-Specific Considerations

The 2024 European Society for Paediatric Anaesthesiology guidelines recommend intravenous ketorolac at 0.5-1 mg/kg (max 30 mg) for a single intraoperative dose, or 0.15-0.2 mg/kg (max 10 mg) every 6 hours for short-term therapy (maximum 48 hours) 3. Notably, these recommendations are for IV administration only.

Research Evidence

Studies examining ketorolac in children have primarily used intravenous routes 4, 5, 6. A 1997 review recommended IV ketorolac at 0.5 mg/kg followed by 1.0 mg/kg every 6 hours, but explicitly stated that "intramuscular injections are not recommended in children, unless the intravenous route is unavailable" 5.

Critical Safety Concerns

Intramuscular administration in children poses specific problems:

1. Lack of pharmacokinetic data for IM route in pediatrics 1
2. Painful administration - IM injections are generally avoided in pediatric practice when alternatives exist
3. Unpredictable absorption compared to IV route
4. Higher bleeding risk at injection site, particularly concerning given ketorolac's antiplatelet effects

Practical Recommendation

Do not administer ketorolac IM to this 10-year-old patient. Instead:

• If IV access is available: Consider IV ketorolac 0.5 mg/kg (max 30 mg single dose) only if:

  • No renal dysfunction present
  • No bleeding disorder or recent aspirin use
  • Not within 6 months of age
  • Duration limited to ≤48 hours
  • Part of multimodal analgesia with appropriate monitoring

• If no IV access: Use oral NSAIDs (ibuprofen 10 mg/kg every 8 hours) or oral acetaminophen (10-15 mg/kg every 6 hours) 3

• For severe pain requiring parenteral therapy: Establish IV access for appropriate medication administration rather than using IM ketorolac

The combination of FDA contraindication, lack of IM-specific pediatric data, availability of safer alternatives, and the inherent disadvantages of IM administration in children makes this route inappropriate for a 10-year-old patient.